Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Revenue (2018 - 2025)

Historic Revenue for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $11.7 million.

  • Bicycle Therapeutics' Revenue rose 33849.03% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.7 million, marking a year-over-year decrease of 19415.63%. This contributed to the annual value of $1.2 million for FY2024, which is 7735.85% down from last year.
  • Per Bicycle Therapeutics' latest filing, its Revenue stood at $11.7 million for Q3 2025, which was up 33849.03% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Revenue registered a high of $11.7 million during Q3 2025, and its lowest value of -$30.4 million during Q4 2024.
  • For the 5-year period, Bicycle Therapeutics' Revenue averaged around $2.9 million, with its median value being $4.3 million (2021).
  • As far as peak fluctuations go, Bicycle Therapeutics' Revenue surged by 95000.0% in 2022, and later crashed by 29458.33% in 2023.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Revenue stood at $800000.0 in 2021, then surged by 950.0% to $8.4 million in 2022, then crashed by 294.58% to -$16.3 million in 2023, then plummeted by 85.79% to -$30.4 million in 2024, then soared by 138.64% to $11.7 million in 2025.
  • Its last three reported values are $11.7 million in Q3 2025, $2.9 million for Q2 2025, and $10.0 million during Q1 2025.